Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm, Immunexpress and Biocartis Announce Collaboration

Published: Wednesday, December 26, 2012
Last Updated: Wednesday, December 26, 2012
Bookmark and Share
Collaboration to advance development of SeptiCyte® Triage for managing sepsis.

Debiopharm Group™ (Debiopharm), Immunexpress Group and Biocartis have announced a world-wide exclusive, royalty-bearing license for the late-stage development and commercialization of SeptiCyte® Triage - a multiplex gene expression assay for use in Emergency and Intensive Care Units (ICUs) or upon hospital admission to diagnose sepsis early, differentiate sepsis from other forms of inflammation, and determine sepsis severity.

Under the terms of the agreement, Debiopharm will fund the validation and U.S. Food and Drug Administration (FDA) clearance of SeptiCyte® Triage and Biocartis will subsequently fund the development and commercialization of the validated SeptiCyte® Triage assay on its fully integrated molecular diagnostics platform.

This platform - which includes an instrument, communication console, and single use, disposable cartridges - can detect and quantify multiple DNA- or RNA-based biomarkers in a wide variety of patient sample types with minimal user intervention in less than 90 minutes.

As part of the agreement, Debiopharm will complete an equity investment in Immunexpress of AUD 2 million.

“The synergy created by this partnership is not only important for the continued development and future availability of SeptiCyte® Triage - but it also exemplifies Immunexpress’ commitment to innovative science and partnerships that improve outcomes for clinicians and patients”, said Dr Roslyn Brandon, President and CEO, Immunexpress.

Dr Brandon continued, “With accuracy significantly better than procalcitonin, bringing SeptiCyte® Triage onto Biocartis’ revolutionary point-of-need multiplex qRT-PCR platform will enable clinicians to more quickly and accurately identify and triage patients suspected of sepsis».

Greg Parekh, Biocartis’ CEO, commented: “Biocartis is striving to bring more effective, individualized treatments within reach of patients through the availability of high quality diagnostics at the point of need. Sepsis is a major cause of death where timely accurate diagnostic information can make a significant difference in medical outcomes”.

“Debiopharm is enthusiastic to join forces with Immunexpress and Biocartis and to take an additional step in our strong commitment to personalized medicine”, said Thierry Mauvernay, Debiopharm’s delegate of the board, who added, “The collaboration opens the door to exploit synergies between the three companies by addressing this life-threatening condition from different perspectives, particularly from a health economics one. Supporting better management of sepsis may ultimately lead to a reduction in mortality, better outcomes and possibly the discovery of new therapies”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Quartz Bio Supports Debiopharm Group Precision Medicine Bioinformatics
Debiopharm Group™ have signed a one-year collaboration agreement with Quartz Bio.
Friday, July 05, 2013
Cenix BioScience and Debiopharm Sign Research Agreement
Both Companies collaborate to identify predictive biomarkers.
Thursday, May 23, 2013
Debiopharm Group™ and Biocartis embark on a Partnership Aiming at Enhancing Personalized Medicine
- Debiopharm Group™ , a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.
Thursday, April 08, 2010
Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl® to Further Help Prostate Cancer Patients
Debiopharm Group announces the filing of an application with the European Agencies for the approval of its new 6-month formulation of Decapeptyl® (triptorelin pamoate 22.5 mg), a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Thursday, September 25, 2008
Debiopharm and EPFL Sign Research Project Agreement
The project agreement will identify inhibitors of signalling pathways controlling cell fate for cancer treatment.
Monday, September 15, 2008
Debiopharm Signs Canadian Partner for Sanvar®
Debiopharm signs license and supply agreement with Medical Futures Inc. for the Canadian distribution rights to SANVAR® IR.
Friday, February 22, 2008
Scientific News
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
New Imaging Method Reveals Nanoscale Details about DNA
Enhancement to super-resolution microscopy shows orientation of individual molecules, providing a new window into DNA’s structure and dynamics.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Scoliosis Linked to Disruptions in Spinal Fluid Flow
A new study in zebrafish suggests that irregular fluid flow through the spinal column brought on by gene mutations is linked to a type of scoliosis that can affect humans during adolescence.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!